BerGenBio ASA (OSL:BGBIO) Current Deferred Revenue : kr0.00 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is BerGenBio ASA Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

BerGenBio ASA's current deferred revenue for the quarter that ended in Mar. 2024 was kr0.00 Mil.

BerGenBio ASA Current Deferred Revenue Historical Data

The historical data trend for BerGenBio ASA's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BerGenBio ASA Current Deferred Revenue Chart

BerGenBio ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Deferred Revenue

Get a 7-Day Free Trial

BerGenBio ASA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Deferred Revenue	Get a 7-Day Free Trial															-	-	-	-	-

BerGenBio ASA Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of BerGenBio ASA's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BerGenBio ASA (OSL:BGBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (OSL:BGBIO) » Definitions » Current Deferred Revenue

Comparable Companies

Traded in Other Exchanges

0RU5:UK 7BG0:Germany

Address

Mollendalsbakken 9, Bergen, NOR, 5009

Website

https://www.bergenbio.com

BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is d is curently being developed in STK11 mutated NSCLC and severe respiratory infections including COVID-19. .

BerGenBio ASA (OSL:BGBIO) Headlines

No Headlines